Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2008

View Archived Issues

Strong immunosuppression by natural compound improves EAE in mice

New compounds for treating cancer disclosed in recent patent literature

Allergan patent describes new therapeutic agents for glaucoma

New agents for treating neurological disorders reported in recent patents

Mechanism of AMPA receptor antagonist protection against viral encephalomyelitis explored

Topical alpha-linolenic acid demonstrates preclinical activity in dry eye

Multiple targeting yields enhanced preclinical antitumor effects in head and neck cancer

Positive interim data for Sunesis' lead product candidate in platinum-resistant ovarian cancer

Ortho Biotech modifies prescribing information for Procrit following guidance from FDA

Wyeth to conclude collaboration agreement with Curis for Hedgehog agonists in stroke

Oramed successfully completes phase Ib clinical trials of oral insulin capsule

Optimer completes enrollment in phase III clinical trial of prulifloxacin in travelers' diarrhea

DSMB recommends continuation of Opexa's phase IIb TERMS study of Tovaxin in MS

Abbott enters agreement with Genentech, Roche and OSI to develop gene test for Tarceva

Health Canada grants approval to BioMimetic Therapeutics to file DLA for GEM OS1

Monogram signs agreement with Avexa to provide HIV resistance and tropism testing

ChemGenex commences phase II omacetaxine trial in AML patients

M's Science and Eisai enter agreement for sigma receptor agonist SA-4503

European approval of desvenlafaxine in VMS will require more clinical data

FDA Advisory Committee recommends approval of sugammadex

Cerimon and Novartis Pharma enter agreement for proof-of-concept study of Simulect in uveitis

Pharmexa and Ichor enter agreement to codevelop malaria and influenza DNA vaccines

Labopharm initiates phase III clinical trial of tramadol-acetaminophen combination drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...